Literature DB >> 2122126

The effects of high phenylalanine concentration on chick embryonic development.

M L Kirby1, S T Miyagawa.   

Abstract

Cells from a particular portion of the cranial neural crest (cardiac neural crest) migrate from the neural fold into pharyngeal arches 3, 4 and 6, where they provide the support for the endothelium of the aortic arch arteries, and by migration into the outflow tract become involved in septation of the truncus arteriosus. Ablation of the premigratory cardiac neural crest results in persistent truncus arteriosus and other defects reminiscent of the DiGeorge syndrome in man. Removal of a small area of the cardiac neural crest causes a spectrum of heart defects classified together as dextraposed aorta including changes like that of Fallot's tetralogy in man. Some inflow tract anomalies have also been found. Pilot studies injecting phenylalanine into developing chick embryos at a very early stage had little effect on embryo viability or on the incidence of congenital heart defects. However, sham-treated animals produced predominantly small simple ventricular septal defects but phenylalanine-treated embryos had more serious and complex heart anomalies. It is not possible to say yet that congenital heart disease in the offspring of mothers with untreated phenylketonuria is due to phenylalanine-induced damage to the neural crest, but the pilot studies in chick suggest that this idea is worth pursuing.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2122126     DOI: 10.1007/bf01799518

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  19 in total

1.  Induction of experimental phenylketonuria-like conditions in chick embryo. Effect on amino acid concentration in brain, liver and plasma.

Authors:  C Marco; M J Alejandre; M F Zafra; J L Segovia; E Garcia-Peregrin
Journal:  Neurochem Int       Date:  1984       Impact factor: 3.921

2.  Neural crest ablation does not alter pulmonary vein development in the chick embryo.

Authors:  M T Phillips; K Waldo; M L Kirby
Journal:  Anat Rec       Date:  1989-03

3.  Pathogenesis of persistent truncus arteriosus and dextroposed aorta in the chick embryo after neural crest ablation.

Authors:  M Nishibatake; M L Kirby; L H Van Mierop
Journal:  Circulation       Date:  1987-01       Impact factor: 29.690

Review 4.  The migration and differentiation of neural crest cells.

Authors:  J A Weston
Journal:  Adv Morphog       Date:  1970

5.  Alteration of early vascular development after ablation of cranial neural crest.

Authors:  D E Bockman; M E Redmond; M L Kirby
Journal:  Anat Rec       Date:  1989-11

6.  Neural crest cells contribute to normal aorticopulmonary septation.

Authors:  M L Kirby; T F Gale; D E Stewart
Journal:  Science       Date:  1983-06-03       Impact factor: 47.728

Review 7.  Maternal phenylketonuria-chronology of the detrimental effects on embryogenesis and fetal development: pathological report, survey, clinical application.

Authors:  R O Fisch; B Burke; J Bass; T B Ferrara; A Mastri
Journal:  Pediatr Pathol       Date:  1986

8.  Lipid composition of brain myelin from normal and hyperphenylalaninemic chick embryos.

Authors:  M J Alejandre; C Marco; H Ramirez; J L Segovia; E Garcia-Peregrin
Journal:  Comp Biochem Physiol B       Date:  1984

9.  Maternal phenylketonuria and hyperphenylalaninemia. An international survey of the outcome of untreated and treated pregnancies.

Authors:  R R Lenke; H L Levy
Journal:  N Engl J Med       Date:  1980-11-20       Impact factor: 91.245

10.  Cardiovascular anomalies in DiGeorge syndrome and importance of neural crest as a possible pathogenetic factor.

Authors:  L H Van Mierop; L M Kutsche
Journal:  Am J Cardiol       Date:  1986-07-01       Impact factor: 2.778

View more
  1 in total

1.  Cardiac teratogenicity in mouse maternal phenylketonuria: defining phenotype parameters and genetic background influences.

Authors:  Nikki J Seagraves; Kim L McBride
Journal:  Mol Genet Metab       Date:  2012-08-08       Impact factor: 4.797

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.